Claus Crone Fuglsang, Novonesis šŸ‡©šŸ‡° | Biosolutions, Industrial biotech, Synbio | E53
Flot.bio x Philip Hemme

Claus Crone Fuglsang, Novonesis šŸ‡©šŸ‡° | Biosolutions, Industrial biotech, Synbio | E53

2026-02-17
Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is for biosolutions startups to scale up.ā­ļø ABOUT THE SPEAKERClaus first joined Novozymes in 1993 and led its R&D both in Denmark and the US, with six years as CSO. He has a Master’s degree in biochemistry and an MBA.šŸ”—Ā LINKS MENTIONEDNovonesis’ website — https://www.novonesis.com/enMerger of Novozymes and C...
View more
Comments (3)

More Episodes

All Episodes>>

Get this podcast on your phone, Free

Create Your Podcast In Minutes

  • Full-featured podcast site
  • Unlimited storage and bandwidth
  • Comprehensive podcast stats
  • Distribute to Apple Podcasts, Spotify, and more
  • Make money with your podcast
Get Started
It is Free